Axon Enterprise, Inc. (NASDAQ:AXON) CEO Patrick W. Smith Sells 53,683 Shares

Axon Enterprise, Inc. (NASDAQ:AXONGet Rating) CEO Patrick W. Smith sold 53,683 shares of the company’s stock in a transaction on Monday, January 23rd. The stock was sold at an average price of $190.17, for a total value of $10,208,896.11. Following the transaction, the chief executive officer now directly owns 2,475,880 shares in the company, valued at $470,838,099.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Axon Enterprise Price Performance

NASDAQ:AXON opened at $188.96 on Wednesday. Axon Enterprise, Inc. has a one year low of $82.49 and a one year high of $194.80. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.39 and a current ratio of 2.79. The firm has a market cap of $13.45 billion, a price-to-earnings ratio of 130.32 and a beta of 0.79. The firm’s fifty day moving average is $177.62 and its two-hundred day moving average is $146.37.

Axon Enterprise (NASDAQ:AXONGet Rating) last posted its quarterly earnings results on Tuesday, November 8th. The biotechnology company reported $0.30 EPS for the quarter, beating the consensus estimate of $0.06 by $0.24. Axon Enterprise had a net margin of 9.75% and a return on equity of 9.88%. The company had revenue of $311.75 million for the quarter, compared to analyst estimates of $276.99 million. Research analysts expect that Axon Enterprise, Inc. will post 0.54 EPS for the current year.

Institutional Investors Weigh In On Axon Enterprise

Several hedge funds have recently modified their holdings of AXON. American Century Companies Inc. boosted its stake in shares of Axon Enterprise by 103.8% during the 1st quarter. American Century Companies Inc. now owns 6,194 shares of the biotechnology company’s stock worth $853,000 after acquiring an additional 3,155 shares in the last quarter. Private Advisor Group LLC boosted its stake in shares of Axon Enterprise by 40.3% during the 1st quarter. Private Advisor Group LLC now owns 3,458 shares of the biotechnology company’s stock worth $476,000 after acquiring an additional 994 shares in the last quarter. Great West Life Assurance Co. Can boosted its stake in shares of Axon Enterprise by 12.3% during the 1st quarter. Great West Life Assurance Co. Can now owns 37,062 shares of the biotechnology company’s stock worth $5,247,000 after acquiring an additional 4,048 shares in the last quarter. Raymond James Trust N.A. boosted its stake in shares of Axon Enterprise by 4.7% during the 1st quarter. Raymond James Trust N.A. now owns 3,753 shares of the biotechnology company’s stock worth $517,000 after acquiring an additional 168 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Axon Enterprise by 2.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 236,287 shares of the biotechnology company’s stock worth $32,545,000 after acquiring an additional 4,897 shares in the last quarter. 75.62% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

AXON has been the topic of several research reports. Morgan Stanley upped their target price on Axon Enterprise from $130.00 to $155.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 13th. Credit Suisse Group upped their target price on Axon Enterprise from $152.00 to $200.00 and gave the company an “outperform” rating in a research report on Tuesday, January 10th. Needham & Company LLC upped their target price on Axon Enterprise from $130.00 to $200.00 and gave the company a “buy” rating in a research report on Wednesday, November 9th. Robert W. Baird upped their target price on Axon Enterprise from $170.00 to $200.00 in a research report on Thursday, December 15th. Finally, StockNews.com initiated coverage on Axon Enterprise in a research report on Wednesday, October 12th. They issued a “hold” rating on the stock. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, Axon Enterprise currently has a consensus rating of “Moderate Buy” and a consensus price target of $181.13.

About Axon Enterprise

(Get Rating)

Axon Enterprise, Inc engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services.

Further Reading

Insider Buying and Selling by Quarter for Axon Enterprise (NASDAQ:AXON)

Receive News & Ratings for Axon Enterprise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axon Enterprise and related companies with MarketBeat.com's FREE daily email newsletter.